23 November 2015 - Elocta, a recombinant factor VIII Fc fusion protein with an extended half-life, will be the first haemophilia A treatment in the EU to offer prolonged protection against bleeding episodes with prophylactic injections every three to five days.

For more details, go to: http://media.biogen.com/press-release/corporate/sobi-and-biogens-elocta-rfviiifc-approved-europe-treatment-haemophilia